---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-255130"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:56:01.933448+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Viridian Q3 net loss $76.7M; positive phase 3 TED data, VRDN-008 best-in-class NHP profile

## Summary
- Q3 net loss $76.7M vs $47.7M YoY; cash $753.2M, net proceeds $243.2M from Sep offering; runway into H2 2027.
- Positive phase 3 THRIVE data for veligrotug in active TED; THRIVE-2 topline expected Dec 2024.
- Initiated phase 3 REVEAL-1 and REVEAL-2 for VRDN-003; topline data anticipated H1 2026.
- VRDN-008 NHP data: 3x half-life vs efgartigimod, 20% deeper IgG reduction; IND planned year-end 2025.
- VRDN-006 IND submission by year-end 2024; proof-of-concept IgG reduction data in H2 2025.

## SEC filing metadata
- accession: 0001193125-24-255130
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/0001193125-24-255130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/d911553d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-255130
- JSON: https://secwatch.observer/filing/0001193125-24-255130.json
- Plain text: https://secwatch.observer/filing/0001193125-24-255130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.